Sociedad Americana de Hirudoterapia

Hirudin, a new therapeutic tool?

Research article published in Annals of hematology (1991)

Última actualización: March 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Desarrollo de fármacosEnsayos clínicosBichler J, Fritz H · Annals of hematology, 1991

Abstract

Hirudin is the most potent natural inhibitor of thrombin known to date. It is gaining popularity as an anticoagulant now that recombinant and synthesized forms are available. It is a monospecific and co-factor-independent thrombin inhibitor with otherwise inert pharmacological properties. Being a surprisingly weak immunogen, its administration has exhibited no side effects, particularly on platelets. Bleeding complications are not to be expected at therapeutic doses. Effective anticoagulatory doses can be easily predicted and laboratory control is no problem. Application of hirudin or derivatives thereof may be indicated for: prophylaxis and treatment of postoperative venous thrombosis and diffuse microthrombosis; prevention of arterial thrombosis, especially in cardiac surgery; enhancement of fibrinolytic therapy and/or angioplasty to prevent reocclusion; extracorporeal circulation; and plastic surgery. Hirudin may be a particularly useful alternative anticoagulatory agent in patients sensitized to heparin or in patients with hereditary or acquired antithrombin III deficiency. However, whether hirudin is really an effective therapeutic tool and whether it can replace heparin in certain clinical indications can be judged only after extended clinical experience has been accumulated.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeComparative StudyJournal ArticleReview
Indexed MeSH termsAnimalsBlood CoagulationExtracorporeal CirculationHeparinHirudin TherapyHirudinsHumansThrombinThrombosis

Resumen

Hirudin is the most potent natural inhibitor of thrombin known to date. It is gaining popularity as an anticoagulant now that recombinant and synthesized forms are available.

Por qué esto importa para la hirudoterapia

Relevant to the development and clinical application of leech-derived pharmaceutical compounds.

Citación

Hirudin, a new therapeutic tool?

Bichler J, Fritz H · Annals of hematology, 1991

Contexto clínico relacionado

Añadido a la biblioteca ASH: March 18, 2026 · Última actualización del sitio: March 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.

Hirudin, a new therapeutic tool? | ASH